MEAGAN PICKETT: Open Payments
NPI 1770295735 · KOSCIUSKO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$465 in 23 payments from 8 companies in 2025. Trend: 2023 $519 · 2024 $1,122 · 2025 $465
Food & beverage: $465
| Company | Payments | Amount |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 8 | $218 |
| ABBVIE INC. | 5 | $79 |
| Novo Nordisk Inc | 3 | $51 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
Products named: NUZYRA, Ozempic, UBRELVY, TRELEGY ELLIPTA, CAPLYTA, AIRSUPRA, BREZTRI, CREON.
Industry payments across MS — which companies pay providers there.
